Gregory

Biography

Mr. Weaver joined the Egalet board of directors effective February 5, 2014, the date of the listing of our common stock on the NASDAQ Global Market. As of October 2017, Mr. Weaver is Chief Financial Officer of Eloxx Pharmaceuticals, based in Waltham MA and Tel Aviv, Israel. Previously, from October 2015 to August 2017 Mr. Weaver served as CFO of Prometic Life Sciences, headquartered in Quebec, publicly traded on the TSX, focused on blood protein therapeutics for treatment of rare diseases. From January 2015 to September 2015 Mr. Weaver served as executive vice president and chief financial officer of Oryzon Genomics, a clinical stage biopharmaceutical company developing therapeutics in oncology and CNS diseases, based in Barcelona and listed on the Madrid exchange. From September 2013 to October 2014, Mr. Weaver served as the chief financial officer, senior vice president, treasurer and corporate secretary of Fibrocell Science, Inc., a publicly held cell therapy company. From June 2011 to July 2013, Mr. Weaver served as senior vice president and chief financial officer of Celsion Corporation, a publicly held biotechnology company, and was a director and chairman of the audit committee of Celsion’s Board of Directors from 2005 to 2011. From February 2009 to September 2010, Mr. Weaver served as senior vice president and chief financial officer of Poniard Pharmaceuticals, a public oncology drug development company. From February 2007 to February 2009, Mr. Weaver served as chief financial officer of Talyst, Inc., a privately-held pharmacy information product company. In 2006 he served as senior vice president and chief financial officer of Sirna Therapeutics, a public RNA therapeutics company until it was acquired by Merck & Co. in December 2006. From 2002 to 2005, Mr. Weaver was chief financial officer of Nastech Pharmaceuticals, a public drug delivery company. From 1999 to 2002, Mr. Weaver was chief financial officer of Ilex Oncology Inc., a public oncology drug development company, and from 1996 to 1999, he was chief financial officer of Prism Technologies, a privately held medical device company. Prior to that, Mr. Weaver held increasingly senior positions with Fidelity Capital and Arthur Andersen LLP. Mr. Weaver currently serves on the board of directors and audit committee of Atossa Genetics, a publicly held diagnostics company. Mr. Weaver is a certified public accountant and received an M.B.A. from Boston College and a B.S. in accounting from Trinity University

Research Interest

Biomedical Sciences